Comparative Pharmacology
Head-to-head clinical analysis: KLONOPIN versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLONOPIN versus PAXIPAM.
KLONOPIN vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that binds to GABA-A receptors at the benzodiazepine binding site, enhancing the effect of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and decreased neuronal excitability.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
0.5 mg orally three times daily; maximum 20 mg/day
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
30-40 hours in adults; prolonged in elderly (up to 50-80 hours) and hepatic impairment; clinical context: steady-state achieved in 5-10 days
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Renal excretion: ~50-70% as glucuronide metabolites, ~30% as unchanged drug (with enterohepatic recirculation); fecal: <2%
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category C
Category C
Benzodiazepine
Benzodiazepine